Robotic surgery for prostate cancer is widespread in the United States

A new study reveals widespread adoption in the United States of robot-assisted prostatectomy to treat prostate cancer in recent years. The study also found that while such surgeries are more expensive than traditional surgeries, their costs are decreasing over time.

In 2001, surgeons began using robotic technologies in procedures to remove the prostate. To examine trends in the use of robotic-assisted radical prostatectomy (RARP) procedures for prostate cancer patients, Steven Chang, MD, MS, of Harvard Medical School, the Dana-Farber Cancer Institute, and Brigham and Women's Hospital, in Boston, Massachusetts, led a team that analyzed 489,369 men who underwent non-RARP (ie, open or laparoscopic radical prostatectomy) or RARP in the United States between 2003 and 2010.

During the study period, RARP adoption (defined as performing more than 50% of annual radical prostatectomies with the robotic approach) increased from 0.7% to 42% of surgeons performing radical prostatectomies.

Surgeons who performed at least 25 radical prostatectomies each year were more likely to adopt RARP. In addition, from 2005 to 2007, adoption was more common among surgeons at teaching hospitals and at intermediate and large-sized hospitals.

After 2007, adoption was more common among surgeons at urban hospitals. RARP was more costly, disproportionally contributing to the 40% increase in annual prostate cancer surgery expenditures; however, RARP costs generally decreased and plateaued at slightly more than $10,000 while non-RARP costs increased to nearly $9,000 by the end of the study.

“Our findings give insights on the adoption of not just robotic technology but future surgical innovations in terms of the general pattern of early diffusion, the potential impact on costs of new and competing treatments, and the alternations in practices patterns such as centralization of care to higher volume providers,” said Chang. The study was published in BJU International (2014; doi:10.1111/bju.12850).

Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs